Literature DB >> 20935211

Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis.

Kátia Daniela da Silveira1, Fernanda Matos Coelho, Angélica Thomáz Vieira, Daniela Sachs, Lívia Corrêa Barroso, Vivian Vasconcelos Costa, Thales Lages Bicalho Bretas, Michael Bader, Lirlândia Pires de Sousa, Tarcília Aparecida da Silva, Robson Augusto Souza dos Santos, Ana Cristina Simões e Silva, Mauro Martins Teixeira.   

Abstract

Activation of the renin-angiotensin (Ang) system induces inflammation via interaction between Ang II and type 1 receptor on leukocytes. The relevance of the new arm of the renin-Ang system, namely Ang-converting enzyme-2/Ang-(1-7)/Mas receptor, for inflammatory responses is not known and was investigated in this study. For this purpose, two experimental models were used: Ag-induced arthritis (AIA) in mice and adjuvant-induced arthritis (AdIA) in rats. Male C57BL/6 wild-type or Mas(-/-) mice were subjected to AIA and treated with Ang-(1-7), the Mas agonist AVE 0991, or vehicle. AdIA was performed in female rats that were given AVE 0991 or vehicle. In wild-type mice, Mas protein is expressed in arthritic joints. Administration of AVE 0991 or Ang-(1-7) decreased AIA-induced neutrophil accumulation, hypernociception, and production of TNF-α, IL-1β, and CXCL1. Histopathological analysis showed significant reduction of inflammation. Mechanistically, AVE 0991 reduced leukocyte rolling and adhesion, even when given after Ag challenge. Mas(-/-) mice subjected to AIA developed slightly more pronounced inflammation, as observed by greater neutrophil accumulation and cytokine release. Administration of AVE 0991 was without effect in Mas(-/-) mice subjected to AIA. In rats, administration of AVE 0991 decreased edema, neutrophil accumulation, histopathological score, and production of IL-1β and CXCL1 induced by AdIA. Therefore, activation of Mas receptors decreases neutrophil influx and cytokine production and causes significant amelioration of arthritis in experimental models of arthritis in rats and mice. This approach might represent a novel therapeutic opportunity for arthritis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20935211     DOI: 10.4049/jimmunol.1000314

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  60 in total

1.  Angiotensin-(1-7) prevents radiation-induced inflammation in rat primary astrocytes through regulation of MAP kinase signaling.

Authors:  Elizabeth D Moore; Mitra Kooshki; Linda J Metheny-Barlow; Patricia E Gallagher; Mike E Robbins
Journal:  Free Radic Biol Med       Date:  2013-09-03       Impact factor: 7.376

2.  Angiotensin IV is induced in experimental autoimmune encephalomyelitis but fails to influence the disease.

Authors:  Arndt Manzel; Oliver Domenig; Bjoern Ambrosius; Agnes Kovacs; Johannes Stegbauer; Marko Poglitsch; Dominik N Mueller; Ralf Gold; Ralf A Linker
Journal:  J Neuroimmune Pharmacol       Date:  2014-05-23       Impact factor: 4.147

Review 3.  The vasoprotective axes of the renin-angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.

Authors:  Xiao C Li; Jianfeng Zhang; Jia L Zhuo
Journal:  Pharmacol Res       Date:  2017-06-12       Impact factor: 7.658

Review 4.  Immunologic Effects of the Renin-Angiotensin System.

Authors:  Steven D Crowley; Nathan P Rudemiller
Journal:  J Am Soc Nephrol       Date:  2017-02-01       Impact factor: 10.121

5.  Angiotensin-converting enzyme 2 (ACE2) activator diminazene aceturate ameliorates endotoxin-induced uveitis in mice.

Authors:  Yiguo Qiu; Pollob Kumar Shil; Ping Zhu; Hongxia Yang; Amrisha Verma; Bo Lei; Qiuhong Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-22       Impact factor: 4.799

6.  Angiotensin II type 2 receptor ligand PD123319 attenuates hyperoxia-induced lung and heart injury at a low dose in newborn rats.

Authors:  Gerry T M Wagenaar; Rozemarijn M A Sengers; El Houari Laghmani; Xueyu Chen; Melissa P H A Lindeboom; Anton J M Roks; Gert Folkerts; Frans J Walther
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-06-20       Impact factor: 5.464

7.  ACE Inhibitors and Sarcopenia: Covering All the BASEs?

Authors:  Jochen Springer; Stephan von Haehling
Journal:  Drugs Aging       Date:  2016-11       Impact factor: 3.923

8.  Suppressing inflammation by inhibiting the NF-κB pathway contributes to the neuroprotective effect of angiotensin-(1-7) in rats with permanent cerebral ischaemia.

Authors:  Teng Jiang; Li Gao; Jun Guo; Jie Lu; Yao Wang; Yingdong Zhang
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

9.  Modulation of brain ACE and ACE2 may be a promising protective strategy against cerebral ischemia/reperfusion injury: an experimental trial in rats.

Authors:  Maha Mohammed Abdel-Fattah; Basim Anwar Shehata Messiha; Ahmed Mohamed Mansour
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-06-17       Impact factor: 3.000

Review 10.  ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis.

Authors:  A C Simões e Silva; K D Silveira; A J Ferreira; M M Teixeira
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.